Skip to search formSkip to main contentSkip to account menu

Vorsetuzumab-mafodotin

Known as: Anti-CD70 MoAb SGN70-MMAF Conjugate 
An antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody, directed against the extracellular domain of the human CD70 molecule… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent Terminology

Narrower (1)

SGN-75

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).
8502Background: Belantamab mafodotin, a B-cell maturation antigen targeting immunoconjugate, demonstrated clinically meaningful… 
2020
2020
DREAMM-1 Patient perspectives from the first-in-human study of single-agent belantamab mafodotin for relapsed and refractory multiple myeloma (RRMM).
e20531Background: Patient-reported outcomes in RRMM remain poor, particularly for those refractory to immunomodulatory agents… 
2020
2020
Anti-BCMA Therapy Endorsed, despite Eye Toxicity.
An FDA advisory committee recommended approval of belantamab mafodotin, a first-in-class BCMA-targeted therapy, to treat patients… 
2018
2018
Clinical and Histological Characterization of Toxic Keratopathy From Depatuxizumab Mafodotin (ABT-414), an Antibody-Drug Conjugate: [RETRACTED].
PURPOSE To report the first histological characterization of microcyst-like epithelial keratopathy (MEK) associated with… 
Review
2016
Review
2016
New monoclonal antibodies for the treatment of acute lymphoblastic leukemia.
2016
2016
A randomized, phase 2 trial of denintuzumab mafodotin and RICE vs RICE alone in the treatment of patients (pts) with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) who are candidates…
TPS7584Background: The only curative option for DLBCL pts who relapse after initial treatment is salvage chemotherapy to obtain… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)